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Abstract
Background: The Montreal Cognitive Assessment (MoCA) was developed to enable earlier detection of mild
cognitive impairment (MCI) relative to familiar multi-domain tests like the Mini-Mental State Exam (MMSE).
Clinicians need to better understand the relationship between MoCA and MMSE scores.
Methods: For this cross-sectional study, we analyzed 219 healthy control (HC), 299 MCI, and 100 Alzheimer’s
disease (AD) dementia cases from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)-GO/2 database to
evaluate MMSE and MoCA score distributions and select MoCA values to capture early and late MCI cases.
Stepwise variable selection in logistic regression evaluated relative value of four test domains for separating MCI
from HC. Functional Activities Questionnaire (FAQ) was evaluated as a strategy to separate dementia from MCI.
Equi-percentile equating produced a translation grid for MoCA against MMSE scores. Receiver Operating
Characteristic (ROC) analyses evaluated lower cutoff scores for capturing the most MCI cases.
Results: Most dementia cases scored abnormally, while MCI and HC score distributions overlapped on each test.
Most MCI cases scored ≥17 on MoCA (96.3 %) and ≥24 on MMSE (98.3 %). The ceiling effect (28–30 points) for MCI
and HC was less using MoCA (18.1 %) versus MMSE (71.4 %). MoCA and MMSE scores correlated most for dementia
(r = 0.86; versus MCI r = 0.60; HC r = 0.43). Equi-percentile equating showed a MoCA score of 18 was equivalent to
MMSE of 24. ROC analysis found MoCA ≥ 17 as the cutoff between MCI and dementia that emphasized high
sensitivity (92.3 %) to capture MCI cases. The core and orientation domains in both tests best distinguished HC from
MCI groups, whereas comprehension/executive function and attention/calculation were not helpful. Mean FAQ scores
were significantly higher and a greater proportion had abnormal FAQ scores in dementia than MCI and HC.
Conclusions: MoCA and MMSE were more similar for dementia cases, but MoCA distributes MCI cases across a
broader score range with less ceiling effect. A cutoff of ≥17 on the MoCA may help capture early and late MCI cases;
depending on the level of sensitivity desired, ≥18 or 19 could be used. Functional assessment can help exclude
dementia cases. MoCA scores are translatable to the MMSE to facilitate comparison.
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Background
Office-based, multi-domain cognitive tests are com-
monly administered in clinical situations to evaluate pa-
tients with cognitive impairment. Galvin and Sadowski
recently wrote clinical recommendations for primary
care physician evaluation of older patients for cognitive
impairment, emphasizing the need to look for early
warning signs where formal cognitive testing can aid de-
tection [1]. Though there are a number of possible tests,
they recommend the Mini-Mental State Examination
(MMSE) [2], the most widely used cognitive screening
test used by physicians for general cognitive evaluation,
and also the newer Montreal Cognitive Assessment
(MoCA) [3]. The MMSE is also commonly used as a
proxy for staging of Alzheimer’s disease (AD) [4].
One problem with the MMSE is its ceiling effect or
limited dynamic performance range for normal indi-
viduals, which increases the likelihood that persons in
predementia stages score within the normal range (24
and above) [5, 6]. Its poor sensitivity for distinguishing
mild cognitive impairment (MCI) is well-described and
can be attributed to a lack of complexity as well as the
absence of executive function items [7–10]. As research
increasingly focuses on milder stages of AD [11], options
other than the MMSE are needed for clinicians for earlier
diagnosis and management.
Though it offers many of the same advantages of the
MMSE, the MoCA was developed as a more challenging
test that includes executive function, higher-level lan-
guage, and complex visuospatial processing to enable
detection of mild impairment with less ceiling effect [3].
Greater sensitivity to detect mild levels of cognitive im-
pairment has been reported for the MoCA in MCI and
AD dementia [3, 12–14], stroke and transient ischemic
attack patients [15] and Parkinson’s disease [16]. Freitas
et al. reported better longitudinal sensitivity for MoCA
than MMSE [13]. Lam et al. found a higher correlation
of the MoCA than MMSE with neuropsychological tests
for memory, executive functioning, visuospatial, and the
Mattis Dementia Rating Scale [17].
The initial MoCA validation study required an MMSE
score of at least 17 for inclusion and used cutoff values of
≤25 on both tests to denote abnormal scores consistent
with amnestic MCI (Peterson criteria) or mild AD [3].
Mean scores in HC, MCI and mild AD dementia groups
were lower on the MoCA than MMSE, though the overall
correlation between tests was high (r = 0.87). MoCA
scores for MCI subjects were detected as abnormal in
73 % of those whose MMSE was normal. The MoCA had
greater sensitivity than MMSE in detecting MCI versus
HCs (90 % versus 18 %); however, specificity was lower for
the MoCA than MMSE (87 % versus 100 %) [3].
Subsequent studies explored lower MoCA cutoff
scores to increase specificity for detection of cognitive
impairment as compared to HCs. Using the Peterson
criteria for amnestic MCI, Luis et al. found that an
MMSE cutoff ≤24 did not distinguish HCs from MCI;
however, the MoCA, using a cutoff of ≤23, with 96 %
sensitivity and 95 % specificity, did [12]. These inves-
tigators and others who have evaluated lower MoCA
cutoff values of ≤23 [12, 18, 19] and ≤20 [20] report
increased detection of impaired MCI cases from HCs
but risk leaving more subtly impaired MCI cases within
the normal range.
Thus, current MoCA literature has focused on MCI
defined more consistent with what is now considered
late MCI. Also, MCI and dementia often comprised a
cognitively impaired group where identifying cutoff
values from HCs were sought. As MCI becomes a more
commonly targeted population for clinical trials, the
ability to capture the full range of MCI cases is crucial.
Further, for clinicians wishing to detect cognitive impair-
ment earlier, knowing the MCI score range using an
office-based test like the MoCA would be very helpful.
More sensitive neuropsychological tests would need to
be applied secondarily to separate those with cognitive
complaints representing the earliest MCI cases from
HCs [21, 22]. Because functional impairment is required
for a dementia diagnosis, this could be a differentiating
feature from MCI when cognitive scores overlap. Accord-
ingly, the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) study has extended the range of their designation
of MCI cases beyond the Peterson criteria to include those
at earlier stages. These early MCI cases often perform in
the normal range on routine office-based tests, such as
the MoCA and MMSE, whereas late MCI cases can score
in the mild dementia range [22].
Our research purpose differed from prior reports com-
paring the MoCA to the MMSE in that we wished to es-
tablish a MoCA score range that captures as many MCI
cases as reasonable, including those at a very early stage,
as designated using ADNI study criteria. We analyzed
the relationship between MoCA and MMSE scores with
their distributions, equivalent scores, cutoff values for
MCI versus AD dementia, and contribution of domain




This is a cross-sectional study analyzing 618 cases from
the ADNI-GO and ADNI-2 databases where both MMSE
and MoCA tests were performed within +/− 90 days of
the clinical diagnosis. Data were downloaded from the
October 2012 release [http://adni.loni.ucla.edu/]. ADNI is
a multi-site, multi-study program funded by a public and
private partnership to investigate whether the combin-
ation of neuroimaging, biological markers, and clinical
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and neuropsychological assessments can accurately track
progression in AD [23]. Data are publicly available to the
scientific community for analyses. Informed consent is
collected through the participating ADNI sites. The
ADNI-GO and ADNI-2 studies were conducted according
to Good Clinical Practice guidelines, US 21CFR Part 50 –
Protection of Human Subjects, and Part 56 – Institutional
Review Boards (IRBs)/Research Ethics Boards (REBs),
and pursuant to state and federal HIPAA regulations.
Study protocols were approved by each site’s IRB/
REB (Additonal file 1). For up-to-date information,
see www.adni-info.org.
At the entry visit into ADNI, cohort subjects received
an initial diagnosis according to certain definitions. AD
dementia subjects had MMSE scores between 20–26
(inclusive), Clinical Dementia Rating Scale (CDR) scores
of either 0.5 or 1.0, and all met National Institute of
Neurological and Communicative Disorders and Stroke/
Alzheimer’s Disease and Related Disorders Association
criteria for probable AD. MCI subjects had a memory
complaint, and MMSE scores between 24–30, objective
memory loss as measured by education-adjusted scores
on the Wechsler Memory Scale (WMS) Logical Memory
II, CDR score of 0.5, absence of significant levels of
impairment in other cognitive domains, essentially pre-
served activities of daily living, and an absence of demen-
tia. In subsequent visits, diagnoses could change and were
not restricted by these entry score ranges on the MMSE.
For our study, follow-up visits (minimum of 6 months
from entry) were used for the MMSE/MoCA study visit in
all except three subjects.
We studied 618 cases from 219 cognitively normal
HC, 299 MCI, and 100 AD dementia cases. Early and
late MCI designations were not distinguished for this
analysis. If there were multiple test measurements within




The MMSE [2] is a widely used cognitive screening test,
where scores from 24 to 30 are considered within the
normal range. Items address orientation, memory, recall,
attention, naming objects, following verbal and written
commands, writing a sentence, and copying a figure.
The MoCA [3] was developed more recently to ad-
dress the shortcomings of the MMSE in detecting MCI.
Its score range is the same as the MMSE (0–30), but has
additional, more complex tasks including executive
function. Items address orientation, drawing figures,
processing speed, naming objects, memory, recall, atten-
tion, vigilance, repetition, verbal fluency, and abstraction.
The MoCA adds one point for those whose educational
level is 12 or fewer years.
Strategy to address MCI overlap scores
We anticipated overlap of the MCI MoCA score range
with the other diagnoses. Therefore, we evaluated whether
other methods could help distinguish HC and AD demen-
tia cases that score in the MCI range on the MoCA using a
functional scale and MMSE and MoCA domain subscores.
The Functional Activities Questionnaire (FAQ) [24]
measures instrumental activities of daily living (IADLs),
such as preparing balanced meals and managing per-
sonal finances. The care partner is interviewed about the
patient’s ability to carry out ten activities. Each activity is
rated on a scale from 0 (normal) to 3 (dependent) with a
maximum total score of 30. Scoring 3 points on at least
3 activities is the recommended cutoff to indicate im-
paired function consistent with dementia [24].
Domains of items (≥4 points per domain) within the
MMSE and MoCA were defined in order to analyze
whether certain components might more heavily contri-
bute to distinguishing MCI from the HC group for each
test. Three domains had items that reflected traditional
neuropsychological constructs (orientation, attention
and calculation, and comprehension/executive function).
The fourth domain, termed “core” was comprised of
items assessing three classic symptoms of AD − naming
(anomia), new learning (amnesia) and visuospatial ability
(agnosia) − reflecting temporoparietal dysfunction that
clinicians can easily assess in the office. Items that were
not similar between the two tests were excluded from
these domains. Items and domains for the MMSE and
MoCA are provided in Table 1.
Statistical analyses
Demographic characteristics, MMSE, MoCA, and FAQ
scores for each diagnostic group are described using
means and standard deviations or frequencies where
appropriate. Scatterplots and Pearson correlations were
applied for better understanding of the relationships
amid the within-case MoCA and MMSE scores for
MCI compared to HCs and AD dementia cases. A
cutoff of ≥24 points for the MMSE and cutoffs of ≥17, 19,
and 23 for the MoCA were denoted in scatterplots to
show the lower ends of the potential MCI score ranges.
We prespecified four domains (orientation, attention
and calculation, comprehension/executive function, and
core) for each test (see Table 1). Stepwise variable selec-
tion in logistic regression was then performed to identify
domains that most contributed to differentiating MCI
from HC for each test.
The equi-percentile equating method with log-linear
smoothing [25] was performed on the MoCA and MMSE
to develop a score conversion table between these scales.
The analysis was performed using the “equate” library in
the R statistical program. Receiver Operating Charac-
teristic (ROC) analysis for MCI versus AD dementia was
Trzepacz et al. BMC Geriatrics  (2015) 15:107 Page 3 of 9
performed to obtain cutoff values with sensitivity and
specificity for MoCA scores. Youden indices are repor-
ted where the highest value reflects balanced sensitivity
and specificity.
All analyses were carried out in SAS version 9.2 unless
specified otherwise.
Results
Table 2 presents demographic, test, and rating scale
scores for each diagnostic group. All groups were highly
educated. There were significant differences between
group means for MMSE, MoCA, and FAQ scores with a
greater degree of impairment in the direction as expected
(dementia >MCI >HC).
Test score distributions
Figure 1 scatterplots show the score distribution relation-
ships between MMSE and MoCA, coded by diagnostic
group and with lines denoting various possible cutoff
scores. The correlation coefficients between tests were
Table 1 Comparison of similar items between MMSE and MoCA
Domain names MMSE MoCA
Items Points Items Points
Orientation Orientation to time and place 10 Orientation to time and place 6
Attention and Calculation Spell WORLD backwardsa 5 Serial 7’s 6
Vigilance test for letter “A”
Digit span (5 forward, 3 backward)
Comprehension/Executive Function Follow 3-stage command 4 Verbal fluency for letter F 4
Trailmaking Test (brief version)
Abstraction (word similarities)Read and obey command
Core Naming (pencil, watch) 6 Naming (lion, rhinoceros, camel) 12
Recall (>10 s delay, 3 words), Recall (5 words after 5 min delay)
Visuoconstructional (copy intersecting pentagons) Visuoconstructional (copy cube and
draw clock face)
Items not included in domains
selected for our analysis
Registration (3 trials, 3 words) 5 Repetition (2 longer sentences) 2
Repetition (1 short sentence)
Write a sentence
Total Score 30 30
Items were selected to comprise domains used in stepwise regression analyses to distinguish MCI from HC subjects
ADNI Alzheimer’s Disease Neuroimaging Initiative, HC healthy control, MCI mild cognitive impairment, MMSE Mini-mental State Exam, MoCA Montreal
Cognitive Assessment
aSerial 7’s were not used for Attention and calculation in the MMSE in ADNI
Table 2 Demographic, cognitive test and scale scores by diagnostic group
Variable HC (n = 219) MCI (n = 299) AD dementia (n = 100) p-value*
Age (years) 77.69 ± 6.24 (63–94) 74.19 ± 7.91 (56–92) 77.58 ± 7.62 (56–92) <.0001
Sex (% male) 50.68 60.87 67.00 .0103
Education (years) 16.42 ± 2.72 (6–20) 16.18 ± 2.76 (8–20) 15.75 ± 3.08 (3–20) .1353
MMSE 29.07 ± 1.24 (23–30) 27.83 ± 1.92 (21–30) 20.31 ± 4.70 (7–30) <.0001
% subjects with MMSE ≥24 99.54 98.33 21.00 <.0001
MoCA 25.57 ± 2.75 (16–30) 23.41 ± 3.38 (13–30) 15.30 ± 5.51 (1–28) <.0001
% subjects with MoCA ≥17 99.54 96.32 48.00 <.0001
% subjects with MoCA ≥19 99.09 90.97 36.00 <.0001
% subjects with MoCA ≥23 87.67 65.89 7.00 <.0001
FAQ 0.30 ± 1.06 (0–10) 3.01 ± 4.20 (0–25) 18.63 ± 6.94 (4–30) <.001
% subjects with abnormal FAQa 0 % 1.7 % 60 % <.001
Data are expressed as mean ± SD (range) except where frequencies are used for categorical data
AD Alzheimer’s disease, ANOVA analysis of variance, HC healthy control, FAQ Functional Activities Questionnaire, MCI mild cognitive impairment, MMSE Mini Mental
State Exam, MoCA Montreal Cognitive Assessment, SD standard deviation
*chi-square test for categorical variables; F test (ANOVA) for continuous variables
aabnormal FAQ defined as at least 3 items each with a score of 3 points
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high for all subjects (0.84) and AD dementia (0.86), but
lower for MCI (0.60) and HC (0.43).
MCI scores were mostly above the cutoff values,
where the lowest MoCA cutoff of ≥17 captured more
MCI cases (96.3 %) than did the higher cutoffs; ≥23
missed a number of MCI cases, though it also captured
the least number of dementia cases. In contrast to the
MoCA, 98.3 % of MCI subjects scored ≥24 on the
MMSE, which is within its published normal range. To
evaluate the known ceiling effect of the MMSE, we also
compared a cutoff of ≥28 on both tests where many
more HC and MCI cases had scores of 28 to 30 on the
MMSE (71.4 %) than on the MoCA (18.1 %).
Scores for AD dementia cases were distributed widely
on both tests, including above and below cutoff lines, re-
vealing a broad range of cognitive impairment severity
despite having a dementia diagnosis.
On each test, HC scores were more tightly distrib-
uted in the upper right quadrants and overlapped
greatly with MCI scores. Nearly all of the HCs scored
in the upper right quadrant with 99.5 % above the
MoCA cutoff of ≥17 and 99.5 % above the MMSE ≥24
cutoff.
Strategies to exclude cases overlapping in the MCI range
FAQ
Mean FAQ scores were significantly different (p < .001)
among diagnostic groups where only the AD dementia
group was in the abnormal range (see Table 2). Abnormal
FAQs were highest in the dementia group (60/100), while
MCI had 5/296 and HC had none. MCI cases with abnor-
mal versus normal FAQs, respectively, had mean scores of
19.6 ± 3.7 and 23.5 ± 3.4 on the MoCA, and 27 ± 2.2 and
27.8 ± 1.9 on the MMSE.
A. All subjects (N=618, r=.84) B. Dementia only (N=100, r=.86)
C. MCI only (N=299, r=.60) D. HC only (N=219, r=.43)
Fig. 1 Scatterplots for MMSE and MoCA scores shown by diagnostic group. Graphs are for all subjects (a), dementia only (b), MCI only (c) and HC
only (d). Pearson correlation coefficients between MMSE and MoCA scores are shown for each graph. Vertical lines denote MMSE standard cutoff
of 24 points and horizontal lines denote different proposed MoCA cutoffs for MCI (17, 19 and 23). Note that symbols may represent more than
one case at that score
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Domain analysis of MoCA and MMSE
Using stepwise logistic regression to select from among the
four prespecified domains, the core domain on both MMSE
and MoCA (p < .0001) followed by the orientation domain
(MMSE, p < .0001 and MoCA, p = .0009) were selected as
contributing significantly to discerning MCI versus HC.
The comprehension/executive function and attention and
calculation domains were not selected for either test.
Translation between MoCA and MMSE scores
Figure 2 describes the equivalent scores when translating
between the MoCA and MMSE tests as analyzed in our
cohort of all subjects using the equi-percentile method,
including a graphic display. A MoCA score of 18 corre-
sponded to an MMSE of 24. MMSE score ranges from
28 to 30 converted to 23–30, and from 22 to 27 to 17–22
on the MoCA. The lowest range on the MoCA (0–16),
where many dementia cases predominated, was repre-
sented by scores of 6–21 on the MMSE, though the small
number of subjects in that lowest score range makes inter-
pretation less confident.
ROC analysis of MoCA scores performed for MCI, as
differentiated from AD dementia, had an AUC of 0.9033
(see Fig. 3). A MoCA cutoff score of 17 emphasized sen-
sitivity (92.3 %) with specificity of 58 %, while a cutoff of
19 had somewhat lower sensitivity (87.3 %) and higher
specificity (77 %). The Youden index was highest (69.9)
for a MoCA cutoff of 20 with the balance of sensitivity
(81.9 %) and specificity (88.0 %).
Discussion
There is growing interest in using the MoCA as an
office-based multi-domain cognitive test in lieu of the
MMSE due to its apparent advantages for assessing cog-
nitively impaired patients in earlier stages, in part attrib-
uted to its greater difficulty and inclusion of executive
function items. Our study purpose was to determine
MoCA scores that captured the range of MCI severity
for clinicians and researchers whereas prior work em-
phasized distinguishing MCI and dementia from HCs.
We found a broader score distribution for MCI subjects
on the MoCA than the MMSE, with a reduced ceiling
effect. This ceiling effect was also reflected by mean test
scores in MCI cases with and without abnormal FAQs
that were almost the same on the MMSE but more dis-
parate on the MoCA. The broader MCI score range on
the MoCA could be useful for earlier detection when
deficits are more subtle and for monitoring cognitive
function over time. We anticipated overlap of MCI with
HCs at the upper range and with dementia cases at the
lower MoCA score range. We realized that applying
another strategy would then be required to separate out
the overlapping HC or dementia cases, similar to the ap-
proach taken by Roalf et al. though they used classifica-
tion [14]. Because much literature still benchmarks AD
cohorts using the MMSE, the way in which MMSE and
MoCA scores translate is important; therefore we also
report equi-percentile conversion scores. We also per-
formed ROC analysis to help determine the lower MCI
cutoff values.
First, we evaluated score distributions and their over-
lap for the MoCA as compared to the MMSE using
ADNI data for 618 cases. The MoCA cutoff of ≥17
points detected most of the MCI cases (96.3 %), similar
to the MMSE using a cutoff of ≥24 (98.3 %). Using the
equi-percentile approach, a MoCA score of 18 was
MoCA Equivalent MMSE MoCA
Equivalent 
MMSE
0 6 16 21
1 9 17 22
2 10 18 24
3 11 19 25
4 12 20 26
5 12 21 27
6 13 22 27
7 14 23 28
8 14 24 29
9 15 25 29
10 15 26 30
11 16 27 30
12 17 28 30
13 18 29 30
14 19 30 30
15 20
Fig. 2 MoCA mapped to MMSE scores using equi-percentile equating method with log-linear smoothing in 618 subjects. Lines in graphs indicate
MMSE cutoff of 24 and MoCA cutoffs of 17 and 19. The MoCA value equivalent to a MMSE cutoff of 24 is shaded
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comparable to MMSE of 24. Using ROC analysis for
MCI versus AD dementia, MoCA cutoff values of ≥17 to
19 were chosen to relatively emphasize sensitivity (92.3
to 87.3 %) over specificity (58 to 77 %). The Youden
index would suggest a MoCA cutoff of 20 if balancing
both (81.9 %, 88.0 %) is desired, which was not the pur-
pose for this study that sought to capture as many MCI
cases as reasonably possible. We recommend a lower
cutoff of ≥17 and upper cutoff of ≤30 points on the
MoCA to capture the range of severity of MCI patients.
However, a lower cutoff of ≥18 or 19 could be used,
depending on the level of sensitivity and specificity that
is desired. Therefore, there is a tight range of MoCA
scores (17–19) that could constitute the lower cutoff for
MCI based on the different ways we examined these
ADNI data.
Many dementia cases were below the cutoffs for MCI
on both scales (<24 MMSE; <17 MoCA); however, 48 %
of the dementia cases were also captured when using the
≥17 MoCA MCI range. This suggests either the level of
cognitive impairment in mild dementia overlaps with
that of more severe MCI or some inconsistency for diag-
nosis when overall clinical judgment using a variety of
inputs is done as in ADNI. Irrespective of the reason, we
recommend that the MoCA be used in conjunction with
a functional measure to help separate the dementia from
MCI cases. Using the published FAQ scoring method of
3 points on at least 3 items [24] to denote functional
impairment, the dementia groups’ scores were predom-
inantly abnormal whereas most of the MCI and all of
the HCs were normal, and the FAQ is easily administered
in a clinical setting.
As expected, the HC score range overlapped with MCI
on both tests, thus the clinician might wish to perform
more sensitive neuropsychological tests or refer such pa-
tients to a neuropsychologist to further evaluate whether
they are healthy or showing early, subtle deficits. An-
other approach to help differentiate MCI from HC is to
use performance on the core and orientation domains of
the MoCA and MMSE, based on our stepwise regres-
sion. Executive function was measured on the MoCA
but did not distinguish these groups though the core do-
main which included recall, naming and visuoconstruc-
tional ability did. Though it would be easy to get domain
subscores in clinical practice, further validation work
should be done including determining cutoff values.
Consistent with a greater ceiling effect on the MMSE
than MoCA, correlations between tests were lower in
the MCI (0.60) and HC (0.43) groups. However, because
test distributions were similar at the recommended cutoffs
and highly correlated in the dementia group (r = .86),
these tests can be considered more comparable for use in
dementia patients.
Our finding potential advantages of the MoCA over
the MMSE in MCI is consistent with a previous report
about the MoCA’s high discriminant potential for MCI
that was significantly different from that for the MMSE
(p = .0007), with an area under the curve (AUC) for the
MoCA of 0.86 compared to 0.75 for the MMSE [13]. By
contrast, they found no difference between the MoCA
and MMSE for AD dementia (p = 0.1018) with an AUC
for the MoCA of 0.98 compared to the MMSE AUC of
0.96 [13], consistent with our finding of a higher correl-
ation between the two scales in the dementia group.
Finally, we used the same equi-percentile equating
method noted in Roalf et al. [14] and in similar diagnos-
tic groups. They translated scores between the MMSE
and MoCA in a geriatric clinic population that was
somewhat younger and less educated than our cohort.
Our findings are remarkably similar to theirs across the
MCI range, with the same MMSE conversion scores for
MoCA 23 and 28, and one point different for MoCA 17
(22 vs 23). Recently, the Roalf equivalency findings were
applied to a racially diverse sample to convert MoCA
to MMSE scores and found to have high correlation
(intraclass correlation coefficient = 0.85, p < .001) when
compared to actual MMSE scores [26]. Thus these
conversions seem to have some consistency across
Fig. 3 ROC analysis graph of MoCA scores for distinguishing MCI
subjects (n = 299) from the AD dementia group (n = 100) and table
for MoCA values to consider as lower cutoff values for MCI (17–20)
depending on sensitivity and specificity levels preferred in a
given situation
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populations. However, our graphic representation re-
vealed an almost linear relationship except at the extreme
of scores, probably because the MMSE is less difficult than
the MoCA, allowing more impaired patients to score a bit
higher at the lower end of the scale, while the least im-
paired scored higher at the upper end (ceiling effect).
Therefore, some caution is advised when interpreting the
low end where very few of our cases were severely demen-
ted, and our conversion was most different from Roalf et
al. [14] in the severe dementia range.
Limitations include our cross-sectional analyses using
ADNI data, which may affect the generalizability. ADNI is
not necessarily reflective of the general population and
has a higher proportion of high cognitive reserve cases,
which is protective of onset of AD symptoms [27]. It may
be that the MoCA would detect MCI even better in the
general population, but this needs to be studied. By ADNI
protocol design, if both the MMSE and MoCA tests were
administered on the same day, the MMSE was adminis-
tered first which could contribute to an order effect that
altered MoCA scores through either a learning effect
for similar items or mental fatigue, especially in demented
patients. However, intervening tests were administered to
reduce a possible learning effect on the few items that
were the same. Since the MoCA is a more difficult test
than the MMSE, detection of cognitive impairment may
be even better when the MoCA is used alone than what is
reported here if an ordering effect had occurred. It should
also be noted that these MCI subjects had a memory com-
plaint making the results relevant only to the amnestic
MCI subtype. We used the diagnosis associated with our
study visit, and not the ADNI entry visit diagnosis when
the MMSE inclusion score criteria would otherwise have
constrained our MoCA analysis. Elapsed time since entry
(at least 6 months) would reduce possible MMSE influ-
ence on later diagnosis.
In summary, we contribute uniquely to the growing lit-
erature on the use of the MoCA for detection of MCI and
its comparison to the MMSE. Based on subjects in ADNI,
we recommend a MoCA score range for MCI using a
lower threshold of ≥17 to ≥19, depending on the levels of
sensitivity and specificity preferred, and an upper limit of
30. Use of a functional tool such as the FAQ can help dis-
cern dementia patients with MoCA scores overlapping in
the MCI range and more sensitive neuropsychological
testing can be done for HCs with overlapping scores.
Though our equi-percentile scores were highly comparable
to those recently reported, which adds to some confidence
to our findings, replication in community populations
would strengthen our recommendations.
Conclusions
We found MMSE scores had a more pronounced ceiling
effect than MoCA for HC and MCI cases. Using ADNI
data, in order to detect a similar number of MCI cases
using an MMSE cutoff of ≥24, the MoCA cutoff needs
to be lowered to between ≥17 to ≥19 depending on the
preference for more sensitivity or specificity versus de-
mentia. The more difficult content in the MoCA may
enhance its sensitivity to detect earlier symptoms when
the upper MCI score is 30. We recommend that the
MoCA be used in conjunction with a functional scale
such as the FAQ to distinguish dementia cases whose
scores overlap in the MCI range and a more sophisti-
cated executive function or episodic memory test to dis-
tinguish milder MCI as it transitions from normal. Also,
based on stepwise regression, testing the orientation or
core domain on either the MMSE or MoCA may help
distinguish HC from MCI cases, though this needs to be
further evaluated in other samples.
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